Amryt confident of following in footsteps of rare disease powerhouse, says CEO

5 December 2017

There are a few striking similarities between the world’s biggest biotech firm focused on rare diseases, and an emerging clinical stage pharma company that was set up just a couple of years ago.

As well as a focus on rare diseases, Amryt Pharma (LSE: AMYT) has Anglo-Irish origins and an acquisitive approach, features in common with Shire (LSE: SHP), the Dublin-headquartered drugmaker.

Amryt’s leadership team also features Shire founder and former chief executive Harry Stratford, and already the company has started to move towards the type of profitability that has allowed Shire to become a rare disease leader.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK